SEC Charges Kiromic BioPharma & Former Execs for Misleading Investors About FDA Roadblocks
In a dramatic enforcement move, the Securities and Exchange Commission (SEC) has taken aim at Kiromic BioPharma, Inc., a Houston-based biotech firm, and two of its former top executives, accusing them of keeping investors in the dark about critical FDA setbacks during a $40 million public offering. While the executives face penalties, the company itself avoided a fine, thanks to its efforts to come clean, cooperate, and make things right after the fact.